(Q39490244)

12 September 2017

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia (English)

1 reference

12 September 2017

2

1 reference

12 September 2017

Roehrborn CG

1

1 reference

12 September 2017

Gould AL

series ordinal

3

1 reference

12 September 2017

Waldstreicher J

series ordinal

4

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

12 September 2017

1 reference

12 September 2017

53

1 reference

12 September 2017

3

1 reference

12 September 2017

581-589

1 reference

The development of human benign prostatic hyperplasia with age

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Parameters of prostate volume and shape in a community based population of men 55 to 74 years old

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Standardized assessment to enhance the diagnostic value of prostate volume; Part II: Correlation with prostate-specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Relationship among age, prostate-specific antigen, and prostate volume in men with lower urinary tract symptoms (LUTS) and in different groups of men with and without benign and malignant prostate diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Intra- and interobserver variability of MRI prostate volume measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900655-4

7 January 2021

10.1016/S0090-4295(98)00655-4

Identifiers

DOI

1 reference

12 September 2017

1 reference